Literature DB >> 8769413

Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype.

K Corrado1, J A Rafael, P L Mills, N M Cole, J A Faulkner, K Wang, J S Chamberlain.   

Abstract

The functional significance of the actin-binding domain of dystrophin, the protein lacking in patients with Duchenne muscular dystrophy, has remained elusive. Patients with deletions of this domain (domain I) typically express low levels of the truncated protein. Whether the moderate to severe phenotypes associated with such deletions result from loss of an essential function, or from reduced levels of a functional protein, is unclear. To address this question, we have generated transgenic mice that express wild-type levels of a dystrophin deleted for the majority of the actin-binding domain. The transgene derived protein lacks amino acids 45-273, removing 2 of 3 in vitro identified actin interacting sites and part of hinge 1. Examination of the effect of this deletion in mice lacking wild-type dystrophin (mdx) suggests that a functional domain I is not essential for prevention of a dystrophic phenotype. However, in contrast to deletions in the central rod domain and to full-length dystrophin, both of which are functional at only 20% of wild-type levels, proteins with a deletion in domain I must be expressed at high levels to prevent a severe dystrophy. These results are also in contrast to the severe dystrophy resulting from truncation of the COOH-terminal domain that links dystrophin to the extracellular matrix. The mild phenotype observed in mice with domain I-deletions indicates that an intact actin-binding domain is not essential, although it does contribute to an important function of dystrophin. These studies also suggest the link between dystrophin and the subsarcolemmal cytoskeleton involves more than a simple attachment of domain I to actin filaments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769413      PMCID: PMC2120962          DOI: 10.1083/jcb.134.4.873

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  57 in total

1.  Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose.

Authors:  J Kyhse-Andersen
Journal:  J Biochem Biophys Methods       Date:  1984-12

2.  Length-tension relationship of mammalian diaphragm muscles.

Authors:  K K McCully; J A Faulkner
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-06

3.  Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy.

Authors:  S B Malhotra; K A Hart; H J Klamut; N S Thomas; S E Bodrug; A H Burghes; M Bobrow; P S Harper; M W Thompson; P N Ray
Journal:  Science       Date:  1988-11-04       Impact factor: 47.728

4.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

5.  The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates.

Authors:  L F Torres; L W Duchen
Journal:  Brain       Date:  1987-04       Impact factor: 13.501

6.  Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies.

Authors:  L L Baumbach; J S Chamberlain; P A Ward; N J Farwell; C T Caskey
Journal:  Neurology       Date:  1989-04       Impact factor: 9.910

7.  The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle.

Authors:  E E Zubrzycka-Gaarn; D E Bulman; G Karpati; A H Burghes; B Belfall; H J Klamut; J Talbot; R S Hodges; P N Ray; R G Worton
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962

8.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

9.  Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice.

Authors:  J E Johnson; B J Wold; S D Hauschka
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

10.  Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex.

Authors:  C G Bönnemann; R Modi; S Noguchi; Y Mizuno; M Yoshida; E Gussoni; E M McNally; D J Duggan; C Angelini; E P Hoffman
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

View more
  26 in total

1.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 3.  Challenges for gene therapy for muscular dystrophy.

Authors:  Jerry R Mendell; K Reed Clark
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

Review 4.  Diverse roles of the actin cytoskeleton in striated muscle.

Authors:  Anthony J Kee; Peter W Gunning; Edna C Hardeman
Journal:  J Muscle Res Cell Motil       Date:  2009-12-08       Impact factor: 2.698

Review 5.  The membrane-cytoskeleton interface: the role of dystrophin and utrophin.

Authors:  S J Winder
Journal:  J Muscle Res Cell Motil       Date:  1997-12       Impact factor: 2.698

6.  Specific interaction of the actin-binding domain of dystrophin with intermediate filaments containing keratin 19.

Authors:  Michele R Stone; Andrea O'Neill; Dawn Catino; Robert J Bloch
Journal:  Mol Biol Cell       Date:  2005-07-06       Impact factor: 4.138

Review 7.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

8.  Dystrophin As a Molecular Shock Absorber.

Authors:  Shimin Le; Miao Yu; Ladislav Hovan; Zhihai Zhao; James Ervasti; Jie Yan
Journal:  ACS Nano       Date:  2018-11-27       Impact factor: 15.881

9.  Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells.

Authors:  Romesh A Draviam; Bing Wang; Juan Li; Xiao Xiao; Simon C Watkins
Journal:  J Muscle Res Cell Motil       Date:  2006-02-23       Impact factor: 2.698

10.  Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery.

Authors:  Louise R Rodino-Klapac; Chrystal L Montgomery; William G Bremer; Kimberly M Shontz; Vinod Malik; Nancy Davis; Spencer Sprinkle; Katherine J Campbell; Zarife Sahenk; K Reed Clark; Christopher M Walker; Jerry R Mendell; Louis G Chicoine
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.